Quick Answer
Anika Therapeutics, Inc. reported Net Income Loss of -$10.88 million for the year ending 2025.
- Anika Therapeutics, Inc. showed an increase of +80.7% in Net Income Loss from 2024 to 2025.
- This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $8.95 million | Q4 2016: $8.09 million | Q1 2017: $5.49 million | Q2 2017: $11.37 million | Q3 2017: $6.89 million | Q4 2017: $8.07 million | Q1 2018: -$6.69 million | Q2 2018: $10.09 million | Q3 2018: $7.60 million | Q4 2018: $7.72 million | Q1 2019: $4.51 million | Q2 2019: $9.44 million | Q3 2019: $9.20 million | Q4 2019: $4.05 million | Q1 2020: $5.79 million | Q2 2020: -$7.71 million | Q3 2020: -$6.41 million | Q4 2020: -$15.66 million | Q1 2021: $2.84 million | Q2 2021: $6.53 million | Q3 2021: $558.0 thousand | Q1 2022: -$2.93 million | Q2 2022: -$2.84 million | Q3 2022: -$4.18 million | Q1 2023: -$10.35 million | Q2 2023: -$2.74 million | Q3 2023: -$6.58 million | Q1 2024: -$4.51 million | Q2 2024: -$88.0 thousand | Q3 2024: -$29.92 million | Q1 2025: -$4.87 million | Q2 2025: -$3.97 million | Q3 2025: -$2.33 million.
- Over the full 17 years of available data (2009 to 2025), Anika Therapeutics, Inc.'s Net Income Loss has declined by 395.0%.
- Historical annual values: Fiscal year 2025: -$10.88 million | Fiscal year 2024: -$56.39 million | Fiscal year 2023: -$82.67 million | Fiscal year 2022: -$14.86 million | Fiscal year 2021: $4.13 million | Fiscal year 2020: -$23.98 million | Fiscal year 2019: $27.19 million | Fiscal year 2018: $18.72 million | Fiscal year 2017: $31.82 million | Fiscal year 2016: $32.55 million | Fiscal year 2015: $30.76 million | Fiscal year 2014: $38.32 million | Fiscal year 2013: $20.58 million | Fiscal year 2012: $11.76 million | Fiscal year 2011: $8.47 million | Fiscal year 2010: $4.32 million | Fiscal year 2009: $3.69 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: